ClinicalTrials.gg
CompletedNCT03653364Updated May 17, 2024Results posted

Study to Assess the Safety, Pharmacokinetics, and Efficacy of Baloxavir Marboxil in Healthy Pediatric Participants From Birth to < 1 Year With Influenza-Like Symptoms

A Phase 3 interventional study of Baloxavir Marboxil in Influenza, sponsored by Hoffmann-La Roche. Completed at 27 sites in 9 countries. Open to participants aged Up to 1 Year. Per ClinicalTrials.gov, last updated 2024-05-17.

Sponsored by Hoffmann-La Roche · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
49
Allocation
Not applicable
Ages
Up to 1 Year
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 18 studies testing baloxavir in Influenza, Human — 7 open to participants now, 7 under way, 5 of them phase 3. baloxavir · Influenza, Human.

Enrollment
17th of 18
49 · median 483
Started
2019
with 3 others
Phase 3
12 of 18
5 open now
Registered
5th of 18
by date
Lead sponsor
7 of 18
Hoffmann-La Roche

Among the 18 studies testing baloxavir in Influenza, Human, this one is the 17th largest by enrollment, is one of 4 that started in 2019, is one of 12 in phase 3, and was the 5th registered.

Influenza, Human

2,358 studies on the registry are indexed under Influenza, Human; 184 are open to participants now.

Browse Influenza, Human studies →

Open to participants now

7 of the 18 studies testing baloxavir in Influenza, Human are open now, in 12 countries. Recruiting first, the newest first:

2 more — sign in →

By country, each count listing its studies:

All 7 open studies →

About baloxavir

baloxavir: first FDA approval 2018 (XOFLUZA), first EMA approval 2021. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 121 Influenza, Human studies recruiting now, 66 (55%) set no upper age limit and 45 (37%) stop at 75 or younger; 33 take children under 18; 67 take healthy volunteers.

This study: Up to 1 Year · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 18 studies testing baloxavir in Influenza, Human, or all of them as a file.
02

Study summary

This study will evaluate the safety, pharmacokinetics and efficacy of baloxavir marboxil in healthy pediatric participants from birth to \<1 year with influenza like symptoms

03

Conditions studied

  • Influenza

Browse trials for

04

Who can participate

Ages eligible
Up to 1 Year
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age from birth to \< 1 year at screening
  • Written for study participation obtained from participant's parents or legal guardian
  • Parent/guardian willing and able to comply with study requirements, in the investigator's judgment
  • Participants with a diagnosis of influenza virus infection confirmed by the presence of all of the following:

    1. In the investigator's judgement there is a clinical suspicion of influenza
    2. At least one respiratory symptom (either cough or coryza)

    (b) Positive prescreening influenza test (RIDT or PCR) performed within 48 hours of screening

  • Participants with a negative prescreening COVID-19 test (RAT or PCR) within 48 hours of screening
  • The time interval between the onset of symptoms and screening is ≤ 96 hours (the onset of symptoms is defined as the time when body temperature first exceeded 37.5°C if known, or the time when the first symptom was noticed by the parent or caregiver)

Exclusion criteria

Exclusion Criteria:

  • Hospitalized for complications of influenza or significant comorbidities
  • Concurrent infections requiring systemic antiviral therapy at screening
  • Require, in the opinion of the investigator, any of the prohibited medication during the study
  • Preterm neonates (born at \< 37 weeks gestation) and/or weighing \< 2.5 kg at screening
  • Previous treatment with peramivir, laninamivir, oseltamivir, zanamivir, or amantadine within 2 weeks prior to screening
  • Immunization with a live/attenuated influenza vaccine during the 2 weeks prior to screening
  • Concomitant treatment with or other immuno-suppressant therapy
  • Known infection or other disorder
  • Uncontrolled renal, vascular, neurologic or metabolic disease (e.g., diabetes, thyroid disorders, adrenal disease), hepatitis, cirrhosis, or pulmonary disease or participants with known chronic renal failure
  • Active cancer at any site
  • History of organ transplant
  • Known to study drug (i.e., baloxavir marboxil) or to acetaminophen
  • Participation in a clinical trial within 4 weeks or five half-lives of exposure to an drug prior to screening, whichever is longer
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
49 participants (actual)

Study arms

  • Experimental
    Baloxavir Marboxil

    Participants will receive single oral dose of baloxavir marboxil on Day 1 (based on body weight and age).

    Drug: Baloxavir Marboxil

Interventions

  • Participants will receive single oral dose of baloxavir marboxil on Day 1 based on body weight and age. Participants aged ≥ 3 months to \<12 months old received baloxavir marboxil, 2 milligrams per kilograms (mg/kg). Participants from birth to \< 4 weeks old and ≥ 4 weeks to \< 3 months old received baloxavir marboxil, 1 mg/kg.

06

What researchers measure

Primary outcomes

  1. Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs)

    An AE is any untoward medical occurrence in a participant or clinical investigation participant administered a pharmaceutical product and that does not necessarily have a causal relationship with this treatment. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with the use of a medicinal (investigational) product, whether or not considered related to the medicinal (investigational) product. A SAE is any significant hazard, contraindication, side effect that is fatal or life-threatening, requires hospitalization or prolongation of an existing hospitalization, results in persistent or significant disability/ incapacity, is a congenital anomaly/ birth defect, is medically significant or requires intervention to prevent one or other of the outcomes listed above.

    Time frame: From Day 1 up to Day 29

Secondary outcomes

  1. Plasma Concentrations of Baloxavir Marboxil and S-033447

    S-033447 is an active metabolite of baloxavir marboxil.

    Time frame: 0.5 to 2 hours post dose on Day 1; 24 hours (Day 2) and 72 hours (Day 4) post dose, Day 6 and Day 10

  2. Area Under the Concentration to Time Curve From Time 0 to Infinity (AUC0-inf) of Baloxavir Marboxil and S-033447

    S-033447 is an active metabolite of baloxavir marboxil.

    Time frame: Up to Day 10

  3. Maximum Plasma Concentration (Cmax) of Baloxavir Marboxil and S-033447

    S-033447 is an active metabolite of baloxavir marboxil.

    Time frame: Up to Day 10

  4. Time to Maximum Plasma Concentration (Tmax) of Baloxavir Marboxil and S-033447

    S-033447 is an active metabolite of baloxavir marboxil.

    Time frame: Up to Day 10

  5. Apparent Half-Life (T1/2) of Baloxavir Marboxil and S-033447

    S-033447 is an active metabolite of baloxavir marboxil.

    Time frame: Up to Day 10

  6. Time to Alleviation of Influenza Signs and Symptoms

    Time to alleviation of influenza signs and symptoms was defined as the length of time taken from the start of treatment to the point at which all of the following criteria were met and remained for at least 21.5 hours: * A score of 0 (no problem) or 1 (minor problem) for cough and nasal symptoms for items 14 and 15 of the Canadian Acute Respiratory Illness and Flu Scale \[CARIFS\]); * A "yes" response to the following question on the CARIFS: "Since the last assessment has the participant been able to return to day care/school, or resume his or her normal daily activity in the same way as performed prior to developing the flu?"; * First return to afebrile state (tympanic temperature ≤37.2 degree Celsius \[°C\]). Median time was estimated from the Kaplan-Meier curve. Participants who withdrew prior to an event of interest or did not experience resolution of symptoms were censored at the last observation time point.

    Time frame: Day 1 up to Day 15

  7. Duration of Fever

    Duration of fever was defined as the length of time taken by participants to return to afebrile state \[tympanic temperature ≤ 37.2°C\] and remaining so for at least 21.5 hours after onset. Participants who did not have fever at baseline or whose body temperature was not collected were excluded from the analysis. Median time was estimated from the Kaplan-Meier curve.

    Time frame: Day 1 up to Day 15

  8. Duration of Symptoms

    The efficacy of baloxavir marboxil was evaluated by duration of symptoms i.e., alleviation of all symptoms as defined by a score of 0 \[no problem\] or 1 \[minor problem\] and remaining so for at least 21.5 hours, for all 18 symptoms (Poor appetite; Not sleeping well; Irritable, cranky, fussy; Feels unwell; Low energy, tired; Not playing well; Crying more than usual; Needing extra care; Clinginess; Headache; Sore throat; Muscle aches or pains; Fever; Cough; Nasal congestion, runny nose; Vomiting; Not interested in what's going on; Unable to get out of bed) specified in the CARIFS questionnaire. Median time was estimated from the Kaplan-Meier curve. Participants who withdrew prior to an event of interest or did not experience resolution of symptoms were censored at the last observation time point.

    Time frame: Day 1 up to Day 15

  9. Time to Return to Normal Health and Activity

    Time to return to normal health and activity was defined by a 'Yes' response to the following question on the CARIFS: "Since the last assessment has the patient been able to return to day care/school or resume his or her normal daily activity in the same way as performed prior to developing the flu?" and remaining so for at least 21.5 hours. Median time was estimated from the Kaplan-Meier curve.Participants who withdrew prior to an event of interest or did not experience resolution of symptoms were censored at the last observation time point.

    Time frame: Day 1 up to Day 15

  10. Number of Participants With Influenza-Related Complications

    The influenza related complications include death, hospitalization, radiologically confirmed pneumonia, bronchitis, sinusitis, otitis media, encephalitis/encephalopathy, febrile seizures, myositis

    Time frame: Day 1 up to Day 29

  11. Number of Participants Requiring Antibiotics

    The number of participants who required antibiotics for influenza related complication are reported here.

    Time frame: Day 1 up to Day 29

  12. Time to Cessation of Viral Shedding by Virus Titer

    Time to cessation of viral shedding by virus titer was defined as the time, in hours, between the initiation of any study treatment and first time when the influenza virus titer was below the limit of detection (0.75 log10 tissue culture infectious dose (TCID)50/milliliters \[mL\]). Participants whose virus titers did not reach the limit by the last observation time point were treated as censored at that time point. One day was converted into 24 hours. Median time was estimated from the Kaplan-Meier curve.

    Time frame: Day 1 up to Day 29

  13. Time to Cessation of Viral Shedding by Reverse Transcription-Polymerase Chain Reaction (RT-PCR)

    Time to cessation of viral shedding by RT-PCR, in hours, was defined as the time between the initiation of study treatment and first time when the virus ribonucleic acid (RNA) by RT-PCR qualitative result was negative (no cycle threshold \[Ct\]-value detectable). Participants who did not have a negative result by the last observation time point were treated as censored at that time point. For the participants with multiple virus types, this endpoint was defined as the time between the initiation of the study treatment and first time when the virus RNA by RT-PCR qualitative result was negative for all virus types. One day was converted into 24 hours. Median time was estimated from the Kaplan -Meier curve. Participants with a positive virus RNA on Day 1 are included in this analysis.

    Time frame: Day 1 up to Day 29

  14. Change From Baseline in Influenza Virus Titer Over Time

    Change from baseline in influenza virus titer (log10TCID50/mL) was defined as the change from baseline in influenza virus titer on Days 2, 4, 6, 10, and 29. If influenza virus titer was less than the lower limit of quantification (LLOQ), the virus titer was imputed as 0.749 (log10TCID50/mL). Only participants with a positive virus titer on Day 1 were included in this analysis.

    Time frame: Baseline, Days 2, 4, 6, 10, and 29

  15. Change From Baseline in the Amount of Virus RNA (RT-PCR) Over Time

    Change from baseline in the amount of virus RNA was defined as the change from baseline in the amount of virus RNA on Days 2, 4, 6 and 10. If the amount of virus RNA is less than the lower limit of quantification, the amount of virus RNA was imputed as the relevant LLOQ (log10 viral particles per mililiter (vp/mL)). If a participant was infected with multiple virus types, the sum of virus RNA (log10 vp/mL) was used for analysis. Participants with a positive virus RNA by RT-PCR on Day 1 were included in this analysis.

    Time frame: Baseline, Days 2, 4, 6, and 10

  16. Percentage of Participants With Positive Influenza Virus Titer Over Time

    Percentage of participants positive for influenza virus titer at each visit were defined as the percentage of participants whose influenza virus titer was not less than the LLOQ (0.75 log10TCID50/mL) or positive among those assessed for influenza virus titer on Days 2, 4, 6, 10 and 29. Participants with a positive influenza virus titer on Day 1 were included in this analysis.

    Time frame: Baseline, Days 2, 4, 6, 10, and 29

  17. Percentage of Participants Positive by RT-PCR Over Time

    Percentage of participants positive by RT-PCR at each visit was defined as the percentage of participants with a positive qualitative result among those assessed by RT-PCR on Days 2, 4, 6, 10 and 29. Participants with a positive RT-PCR result on Day 1 were included in this analysis. Percentages are rounded off.

    Time frame: Baseline, Days 2, 4, 6, 10, and 29

  18. Area Under the Concentration-Time Curve (AUC) in Virus Titer

    AUC in virus titer was calculated using the trapezoidal method. Twenty-four hours of time was converted into one day. Participants with a positive virus titer on Day 1 were included in this analysis. The LLOQ and lower limit of detection was defined as 0.75 log10TCID50/mL for flu A and 0.75 log10TCID50/mL for flu B. If a participant was infected with multiple virus types, the sum of those virus titers will be used for analysis.

    Time frame: Day 1 up to Day 29

  19. Area Under the Curve in the Amount of Virus RNA (RT-PCR)

    AUC in virus RNA (RT-PCR) was defined as AUC of change from baseline in the amount of virus RNA (RT-PCR). AUC was calculated using the trapezoidal method similar to AUC in virus titer. Participants with a positive RT-PCR result on Day 1 were subjected to this analysis. If the amount of virus RNA is less than the lower limit of quantification, the amount of virus RNA was imputed as the relevant LLOQ (log10 viral particles per mililiter (vp/mL)). If a participant was infected with multiple virus types, the sum of those the amount of virus RNA was used for analysis.

    Time frame: Day 1 up to Day 29

07

Results

Posted May 17, 2024

Participant flow

Participants were enrolled in this study at 15 investigative sites in 7 countries (Costa Rica, Finland, Mexico, Poland, South Africa, Spain, and the United States) from 23 January 2019 to 03 April 2023.

Participant flow — Overall Study
MilestoneBaloxavir Marboxil
Started49
Completed46
Not completed3
Withdrew: Withdrawal by subject1
Withdrew: Enrolled in error1
Withdrew: Death1

Outcome measures

PrimaryNumber of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs)

An AE is any untoward medical occurrence in a participant or clinical investigation participant administered a pharmaceutical product and that does not necessarily have a causal relationship with this treatment. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with the use of a medicinal (investigational) product, whether or not considered related to the medicinal (investigational) product. A SAE is any significant hazard, contraindication, side effect that is fatal or life-threatening, requires hospitalization or prolongation of an existing hospitalization, results in persistent or significant disability/ incapacity, is a congenital anomaly/ birth defect, is medically significant or requires intervention to prevent one or other of the outcomes listed above.

Time frame:
From Day 1 up to Day 29
Reported as:
Count of participants · Participants
Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs)
ParticipantsBaloxavir Marboxil
AEs23
SAEs2
SecondaryPlasma Concentrations of Baloxavir Marboxil and S-033447

S-033447 is an active metabolite of baloxavir marboxil.

Time frame:
0.5 to 2 hours post dose on Day 1; 24 hours (Day 2) and 72 hours (Day 4) post dose, Day 6 and Day 10
Reported as:
Mean · nanograms per milliliters (ng/mL)
Plasma Concentrations of Baloxavir Marboxil and S-033447
nanograms per milliliters (ng/mL)Baloxavir Marboxil
Baloxavir Marboxil: 0.5 to 2 hours0.93 ± 2.301
Baloxavir Marboxil: 24 hours0 ± 0
Baloxavir Marboxil: 72 hours0 ± 0
Baloxavir Marboxil: Day 60 ± 0
Baloxavir Marboxil: Day 100 ± 0
S-033447: 0.5 to 2 hours81.98 ± 89.412
S-033447: 24 hours49.75 ± 40.987
S-033447: 72 hours17.88 ± 17.438
S-033447: Day 64.72 ± 3.649
S-033447: Day 101.35 ± 1.547
SecondaryArea Under the Concentration to Time Curve From Time 0 to Infinity (AUC0-inf) of Baloxavir Marboxil and S-033447

S-033447 is an active metabolite of baloxavir marboxil.

Time frame:
Up to Day 10
Reported as:
Mean · nanograms/milliters*hour (ng/mL*hr)
Area Under the Concentration to Time Curve From Time 0 to Infinity (AUC0-inf) of Baloxavir Marboxil and S-033447
nanograms/milliters*hour (ng/mL*hr)Baloxavir Marboxil
Baloxavir MarboxilNA ± NA
S-0334475070 ± 3520
SecondaryMaximum Plasma Concentration (Cmax) of Baloxavir Marboxil and S-033447

S-033447 is an active metabolite of baloxavir marboxil.

Time frame:
Up to Day 10
Reported as:
Mean · nanograms/ milliters (ng/ml)
Maximum Plasma Concentration (Cmax) of Baloxavir Marboxil and S-033447
nanograms/ milliters (ng/ml)Baloxavir Marboxil
Baloxavir MarboxilNA ± NA
S-033447127 ± 81.0
SecondaryTime to Maximum Plasma Concentration (Tmax) of Baloxavir Marboxil and S-033447

S-033447 is an active metabolite of baloxavir marboxil.

Time frame:
Up to Day 10
Reported as:
Median · hours
Time to Maximum Plasma Concentration (Tmax) of Baloxavir Marboxil and S-033447
hoursBaloxavir Marboxil
Baloxavir MarboxilNA (NA to NA)
S-0334474.5 (2.00 to 14.5)
SecondaryApparent Half-Life (T1/2) of Baloxavir Marboxil and S-033447

S-033447 is an active metabolite of baloxavir marboxil.

Time frame:
Up to Day 10
Reported as:
Median · hours
Apparent Half-Life (T1/2) of Baloxavir Marboxil and S-033447
hoursBaloxavir Marboxil
Baloxavir MarboxilNA (NA to NA)
S-03344723.1 (13.0 to 33.4)
SecondaryTime to Alleviation of Influenza Signs and Symptoms

Time to alleviation of influenza signs and symptoms was defined as the length of time taken from the start of treatment to the point at which all of the following criteria were met and remained for at least 21.5 hours: * A score of 0 (no problem) or 1 (minor problem) for cough and nasal symptoms for items 14 and 15 of the Canadian Acute Respiratory Illness and Flu Scale \[CARIFS\]); * A "yes" response to the following question on the CARIFS: "Since the last assessment has the participant been able to return to day care/school, or resume his or her normal daily activity in the same way as performed prior to developing the flu?"; * First return to afebrile state (tympanic temperature ≤37.2 degree Celsius \[°C\]). Median time was estimated from the Kaplan-Meier curve. Participants who withdrew prior to an event of interest or did not experience resolution of symptoms were censored at the last observation time point.

Time frame:
Day 1 up to Day 15
Reported as:
Median · hours
Time to Alleviation of Influenza Signs and Symptoms
hoursBaloxavir Marboxil
Time to Alleviation of Influenza Signs and Symptoms163.7 (122.5 to NA)
SecondaryDuration of Fever

Duration of fever was defined as the length of time taken by participants to return to afebrile state \[tympanic temperature ≤ 37.2°C\] and remaining so for at least 21.5 hours after onset. Participants who did not have fever at baseline or whose body temperature was not collected were excluded from the analysis. Median time was estimated from the Kaplan-Meier curve.

Time frame:
Day 1 up to Day 15
Reported as:
Median · hours
Duration of Fever
hoursBaloxavir Marboxil
Duration of Fever23.1 (22.3 to 44.6)
SecondaryDuration of Symptoms

The efficacy of baloxavir marboxil was evaluated by duration of symptoms i.e., alleviation of all symptoms as defined by a score of 0 \[no problem\] or 1 \[minor problem\] and remaining so for at least 21.5 hours, for all 18 symptoms (Poor appetite; Not sleeping well; Irritable, cranky, fussy; Feels unwell; Low energy, tired; Not playing well; Crying more than usual; Needing extra care; Clinginess; Headache; Sore throat; Muscle aches or pains; Fever; Cough; Nasal congestion, runny nose; Vomiting; Not interested in what's going on; Unable to get out of bed) specified in the CARIFS questionnaire. Median time was estimated from the Kaplan-Meier curve. Participants who withdrew prior to an event of interest or did not experience resolution of symptoms were censored at the last observation time point.

Time frame:
Day 1 up to Day 15
Reported as:
Median · hours
Duration of Symptoms
hoursBaloxavir Marboxil
Duration of Symptoms163.7 (71.0 to NA)
SecondaryTime to Return to Normal Health and Activity

Time to return to normal health and activity was defined by a 'Yes' response to the following question on the CARIFS: "Since the last assessment has the patient been able to return to day care/school or resume his or her normal daily activity in the same way as performed prior to developing the flu?" and remaining so for at least 21.5 hours. Median time was estimated from the Kaplan-Meier curve.Participants who withdrew prior to an event of interest or did not experience resolution of symptoms were censored at the last observation time point.

Time frame:
Day 1 up to Day 15
Reported as:
Median · hours
Time to Return to Normal Health and Activity
hoursBaloxavir Marboxil
Time to Return to Normal Health and Activity140.7 (72.2 to NA)
SecondaryNumber of Participants With Influenza-Related Complications

The influenza related complications include death, hospitalization, radiologically confirmed pneumonia, bronchitis, sinusitis, otitis media, encephalitis/encephalopathy, febrile seizures, myositis

Time frame:
Day 1 up to Day 29
Reported as:
Count of participants · Participants
Number of Participants With Influenza-Related Complications
ParticipantsBaloxavir Marboxil
Number of Participants With Influenza-Related Complications0
SecondaryNumber of Participants Requiring Antibiotics

The number of participants who required antibiotics for influenza related complication are reported here.

Time frame:
Day 1 up to Day 29
Reported as:
Count of participants · Participants
Number of Participants Requiring Antibiotics
ParticipantsBaloxavir Marboxil
Number of Participants Requiring Antibiotics0
SecondaryTime to Cessation of Viral Shedding by Virus Titer

Time to cessation of viral shedding by virus titer was defined as the time, in hours, between the initiation of any study treatment and first time when the influenza virus titer was below the limit of detection (0.75 log10 tissue culture infectious dose (TCID)50/milliliters \[mL\]). Participants whose virus titers did not reach the limit by the last observation time point were treated as censored at that time point. One day was converted into 24 hours. Median time was estimated from the Kaplan-Meier curve.

Time frame:
Day 1 up to Day 29
Reported as:
Median · hours
Time to Cessation of Viral Shedding by Virus Titer
hoursBaloxavir Marboxil
Time to Cessation of Viral Shedding by Virus Titer24.5 (24.2 to 68.6)
SecondaryTime to Cessation of Viral Shedding by Reverse Transcription-Polymerase Chain Reaction (RT-PCR)

Time to cessation of viral shedding by RT-PCR, in hours, was defined as the time between the initiation of study treatment and first time when the virus ribonucleic acid (RNA) by RT-PCR qualitative result was negative (no cycle threshold \[Ct\]-value detectable). Participants who did not have a negative result by the last observation time point were treated as censored at that time point. For the participants with multiple virus types, this endpoint was defined as the time between the initiation of the study treatment and first time when the virus RNA by RT-PCR qualitative result was negative for all virus types. One day was converted into 24 hours. Median time was estimated from the Kaplan -Meier curve. Participants with a positive virus RNA on Day 1 are included in this analysis.

Time frame:
Day 1 up to Day 29
Reported as:
Median · hours
Time to Cessation of Viral Shedding by Reverse Transcription-Polymerase Chain Reaction (RT-PCR)
hoursBaloxavir Marboxil
Time to Cessation of Viral Shedding by Reverse Transcription-Polymerase Chain Reaction (RT-PCR)219.1 (141.6 to 695.5)
SecondaryChange From Baseline in Influenza Virus Titer Over Time

Change from baseline in influenza virus titer (log10TCID50/mL) was defined as the change from baseline in influenza virus titer on Days 2, 4, 6, 10, and 29. If influenza virus titer was less than the lower limit of quantification (LLOQ), the virus titer was imputed as 0.749 (log10TCID50/mL). Only participants with a positive virus titer on Day 1 were included in this analysis.

Time frame:
Baseline, Days 2, 4, 6, 10, and 29
Reported as:
Mean · log10 TCID 50/mL
Change From Baseline in Influenza Virus Titer Over Time
log10 TCID 50/mLBaloxavir Marboxil
Baseline3.58 ± 1.81
Change From Baseline at Day 2-2.50 ± 1.70
Change From Baseline at Day 4-2.60 ± 1.95
Change From Baseline at Day 6-2.43 ± 1.40
Change From Baseline at Day 10-2.83 ± 1.81
Change From Baseline at Day 29-1.69 ± 1.71
SecondaryChange From Baseline in the Amount of Virus RNA (RT-PCR) Over Time

Change from baseline in the amount of virus RNA was defined as the change from baseline in the amount of virus RNA on Days 2, 4, 6 and 10. If the amount of virus RNA is less than the lower limit of quantification, the amount of virus RNA was imputed as the relevant LLOQ (log10 viral particles per mililiter (vp/mL)). If a participant was infected with multiple virus types, the sum of virus RNA (log10 vp/mL) was used for analysis. Participants with a positive virus RNA by RT-PCR on Day 1 were included in this analysis.

Time frame:
Baseline, Days 2, 4, 6, and 10
Reported as:
Mean · log10 vp/mL
Change From Baseline in the Amount of Virus RNA (RT-PCR) Over Time
log10 vp/mLBaloxavir Marboxil
Baseline6.46 ± 1.91
Change From Baseline at Day 2-2.26 ± 1.00
Change From Baseline at Day 4-1.93 ± 1.99
Change From Baseline at Day 6-1.76 ± 2.40
Change From Baseline at Day 10-3.30 ± 3.46
SecondaryPercentage of Participants With Positive Influenza Virus Titer Over Time

Percentage of participants positive for influenza virus titer at each visit were defined as the percentage of participants whose influenza virus titer was not less than the LLOQ (0.75 log10TCID50/mL) or positive among those assessed for influenza virus titer on Days 2, 4, 6, 10 and 29. Participants with a positive influenza virus titer on Day 1 were included in this analysis.

Time frame:
Baseline, Days 2, 4, 6, 10, and 29
Reported as:
Number · percentage of participants
Percentage of Participants With Positive Influenza Virus Titer Over Time
percentage of participantsBaloxavir Marboxil
Baseline100
Day 240
Day 420
Day 630
Day 100
Day 290
SecondaryPercentage of Participants Positive by RT-PCR Over Time

Percentage of participants positive by RT-PCR at each visit was defined as the percentage of participants with a positive qualitative result among those assessed by RT-PCR on Days 2, 4, 6, 10 and 29. Participants with a positive RT-PCR result on Day 1 were included in this analysis. Percentages are rounded off.

Time frame:
Baseline, Days 2, 4, 6, 10, and 29
Reported as:
Number · percentage of participants
Percentage of Participants Positive by RT-PCR Over Time
percentage of participantsBaloxavir Marboxil
Baseline100
Day 292.3
Day 492.3
Day 664.3
Day 1042.9
Day 290
SecondaryArea Under the Concentration-Time Curve (AUC) in Virus Titer

AUC in virus titer was calculated using the trapezoidal method. Twenty-four hours of time was converted into one day. Participants with a positive virus titer on Day 1 were included in this analysis. The LLOQ and lower limit of detection was defined as 0.75 log10TCID50/mL for flu A and 0.75 log10TCID50/mL for flu B. If a participant was infected with multiple virus types, the sum of those virus titers will be used for analysis.

Time frame:
Day 1 up to Day 29
Reported as:
Mean · log10 TCID 50/mL*hours
Area Under the Concentration-Time Curve (AUC) in Virus Titer
log10 TCID 50/mL*hoursBaloxavir Marboxil
Area Under the Concentration-Time Curve (AUC) in Virus Titer405.23 ± 184.72
SecondaryArea Under the Curve in the Amount of Virus RNA (RT-PCR)

AUC in virus RNA (RT-PCR) was defined as AUC of change from baseline in the amount of virus RNA (RT-PCR). AUC was calculated using the trapezoidal method similar to AUC in virus titer. Participants with a positive RT-PCR result on Day 1 were subjected to this analysis. If the amount of virus RNA is less than the lower limit of quantification, the amount of virus RNA was imputed as the relevant LLOQ (log10 viral particles per mililiter (vp/mL)). If a participant was infected with multiple virus types, the sum of those the amount of virus RNA was used for analysis.

Time frame:
Day 1 up to Day 29
Reported as:
Mean · log10 vp/mL*hours
Area Under the Curve in the Amount of Virus RNA (RT-PCR)
log10 vp/mL*hoursBaloxavir Marboxil
Area Under the Curve in the Amount of Virus RNA (RT-PCR)779.06 ± 426.83

Adverse events

Collected over Day 1 up to Day 29. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Baloxavir Marboxil1/48 (2.1%)2/48 (4.2%)11/48 (22.9%)
Most frequent serious events
Most frequent serious events
EventBaloxavir Marboxil
Lower respiratory tract infectionInfections and infestations1/48
ChokingRespiratory, thoracic and mediastinal disorders1/48
Most frequent other events
Most frequent other events
EventBaloxavir Marboxil
DiarrhoeaGastrointestinal disorders8/48
VomitingGastrointestinal disorders6/48

Baseline characteristics

Safety-evaluable population included all participants who received at least one dose of treatment regardless of whether they had any follow-up assessments.

Age, Continuous
Age, Continuous(days)Baloxavir Marboxil
Mean206.5 ± 106.08
Sex: Female, Male
Sex: Female, Male(Participants)Baloxavir Marboxil
Female23
Male25
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Baloxavir Marboxil
Hispanic or Latino15
Not Hispanic or Latino22
Unknown or Not Reported11
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Baloxavir Marboxil
American Indian or Alaska Native1
Asian0
Native Hawaiian or Other Pacific Islander0
Black or African American26
White21
More than one race0
Unknown or Not Reported0
08

Study locations

27 sites
  • The Children's Clinic of Jonesboro, P.A.
    Jonesboro, Arkansas 72401, United States
  • Usf Health
    Tampa, Florida 33606, United States
  • Clinical Research Prime
    Idaho Falls, Idaho 83404, United States
  • Ann & Robert H. Lurie Children's Hospital of Chicago;Division of Infectious Disease
    Chicago, Illinois 60611, United States
  • Kentucky Pediatric Research Center
    Bardstown, Kentucky 40004, United States
  • Oak Cliff Research Company, LLC
    Dallas, Texas 75218, United States
  • Mercury Clinical Research
    Houston, Texas 77036-3316, United States
  • Tekton Research
    San Antonio, Texas 78229, United States
  • MHAT Stamen Iliev AD
    Montana, 3400, Bulgaria
  • SHAT for Pneumo-Phtysiatric Diseases ?Dr. Dimitar Gramatikov?; Dept. of Pulmonology and Phtisiatrics
    Ruse, 7002, Bulgaria
  • ICIMED Instituto de Investigación en Ciencias Médicas
    San José, 10108, Costa Rica
  • TAYS Lastenklinikka; Lasten lääketutkimuskeskus Peetu
    Tampere, 33520, Finland
  • Clalit Health Services- Pediatric Ambulatory Clinic; Pediatric Ambulatory Clinic
    Petach Tikva, 4931807, Israel
  • NZOZ Salmed
    ??czna, 21-010, Poland
  • Samodzielny Zespol Publicznych Zakladow Opieki Zdrowotnej im. Dzieci Warszawy w Dziekanowie Lesnym
    ?omianki, 05-092, Poland
  • Wojewodzki Szpital Obserwacyjno-Zakazny; Oddzia? Pediatrii, Chorób Infekcyjnych i Hepatologii
    Bydgoszcz, 85-030, Poland
  • IN VIVO Sp. z o.o.
    Bydgoszcz, 85-048, Poland
  • NZOZ Vitamed
    Bydgoszcz, 85-079, Poland
  • The scientific-research institute of epidemiology; Infectious clinical hospital ?2 of Moscow H.D.
    Moskva, Moskovskaja Oblast 111123, Russian Federation
  • Global Clinical Trials; Clinical Trials
    Gauteng, 0001, South Africa
  • GAMA; Clinical Research
    Germiston, 1401, South Africa
  • Peermed Clinical Trial Centre
    Kempton Park, 1619, South Africa
  • Metropolitan Clinical Research Institute
    Polokwane, 0699, South Africa
  • Pholosho Netcare; Netcare Hospital
    Polokwane, 0699, South Africa
  • Setshaba Research Centre; Clinical Research
    Pretoria, 0152, South Africa
  • Complejo Hospitalario Universitario de Santiago (CHUS); Area Asistencial Integrada de Pediatría
    Santiago de Compostela, LA Coruña 15706, Spain
  • Hospital Universitario 12 de Octubre; Servicio de Pediatria
    Madrid, 28041, Spain
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jan 2019 to primary completion in Apr 2023, 50 months.

Results were first posted in May 2024, 1 year 1 month after primary completion.

Of 119 industry-sponsored phase 3 interventional studies under Influenza, Human, half reached primary completion within 8 months of starting (the median), counting those still running; a quarter within 3 and three quarters within 14. This study's 50 months is above that.

Counting every sponsor, half of 154 studies reached it within 8 months; a quarter within 4 and three quarters within 15.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 29, 2018
First posted
Aug 31, 2018
StartActual
Jan 23, 2019
Primary completionActual
Apr 3, 2023
CompletionActual
Apr 3, 2023
Results first posted
May 17, 2024
Last update
May 17, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 17, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03653364
Lead sponsor
Hoffmann-La Roche
Responsible party
Sponsor
First posted
Aug 31, 2018
Start date
Jan 23, 2019
Primary completion
Apr 3, 2023
Completion
Apr 3, 2023
Results posted
May 17, 2024
Last update
May 17, 2024

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Baloxavir

Start the discussion